BioNTech

BioNTech SE is a global biotechnology company focused on developing next-generation immunotherapies, mRNA-based medicines, and precision oncology treatments. Founded in 2008 and headquartered in Mainz, Germany, BioNTech has become one of Europe’s most influential biotechnology innovators. The company combines cutting-edge molecular biology, artificial intelligence, computational biology, genomics, and immunology to create personalized therapies for cancer and infectious diseases.

BioNTech gained worldwide recognition through the development of one of the first approved mRNA COVID-19 vaccines in collaboration with Pfizer. Building on this achievement, the company has significantly expanded its research pipeline into oncology, infectious diseases, regenerative medicine, rare diseases, and next-generation immunotherapies. Its proprietary technology platforms include mRNA therapeutics, cell therapies, antibody-based treatments, and individualized cancer vaccines.

The company operates research centers, manufacturing facilities, and commercial operations across Europe, North America, and Asia while maintaining strategic partnerships with leading pharmaceutical companies and academic institutions. BioNTech continues to invest heavily in scientific research, advanced manufacturing technologies, and global clinical development programs. Through its commitment to innovation, quality, and patient-centered healthcare, BioNTech is helping shape the future of precision medicine and personalized healthcare while addressing some of the world’s most challenging diseases.